BiotechTube

Afamelanotide 16mg implant

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Erythropoietic Protoporphyria

Conditions

Erythropoietic Protoporphyria

Trial Timeline

Mar 7, 2024 → Jan 20, 2025

NCT ID
NCT06388642

About Afamelanotide 16mg implant

Afamelanotide 16mg implant is a phase 1/2 stage product being developed by Clinuvel Pharmaceuticals for Erythropoietic Protoporphyria. The current trial status is completed. This product is registered under clinical trial identifier NCT06388642. Target conditions include Erythropoietic Protoporphyria.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT06388642Phase 1/2Completed

Competing Products

8 competing products in Erythropoietic Protoporphyria

See all competitors
ProductCompanyStageHype Score
DISC-1459 + DISC-1459 + PlaceboDisc MedicinePhase 2
47
Placebo + DISC-1459Disc MedicinePhase 3
72
DISC-1459 + DISC-1459Disc MedicinePhase 2/3
60
AfamelanotideClinuvel PharmaceuticalsPhase 3
69
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3
69
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3
69
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 2
44
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3
69

Other Products from Clinuvel Pharmaceuticals

AfamelanotidePhase 3
69
Afamelanotide + PlaceboPhase 3
69
Afamelanotide + PlaceboPhase 3
69
Afamelanotide + PlaceboPhase 3
69
Afamelanotide + PlaceboPhase 3
69